Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR446597 in Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of SAR446597 in geographic atrophy (GA) (4 arms), sponsored by Sanofi. Primary endpoints: Incidence and severity of ocular and non-ocular treatment-emergent adverse events and Incidence and severity of ocular and non-ocular treatment-emergent serious adverse events. Started Oct 2025; status: recruiting.
02
Drugs
SAR446597
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT07215234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215234.